Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shannon Chang

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
The American Journal of Gastroenterology|November 17, 2023
Changes in Therapy Are Not Associated With Increased Remission in Patients With Crohn's Disease of the PouchMaia Kayal, Parakkal Deepak, Poonam Beniwal-Patel, et al.
Crohn'S & Colitis 360|July 31, 2023
Dietary Patterns Are Not Associated With Disease Activity Among Patients With Inflammatory Conditions of the Pouch in a Prospective CohortEdward L Barnes, Poonam Beniwal-Patel, Parakkal Deepak, et al.
Crohn'S & Colitis 360|September 9, 2022
Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter RegistryEdward L Barnes, Parakkal Deepak, Poonam Beniwal-Patel, et al.
Inflammatory Bowel Diseases|July 22, 2024
Risankizumab Is Effective for The Management of Crohn's Disease of the PouchMaia Kayal, Elizabeth A Spencer, Matthew Smyth, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 15, 2019
Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel DiseasesJordan E Axelrad, Ahmad Bazarbashi, James Zhou, et al.
The American Journal of Gastroenterology|June 25, 2025
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the PouchEdward L Barnes, Laura Raffals, Taha Qazi, et al.
Therapeutic Advances in Gastroenterology|November 9, 2022
COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control studySimon J Hong, Sumona Bhattacharya, Aiya Aboubakr, et al.
Digestive Diseases and Sciences|September 16, 2025
Safety and Efficacy of Ustekinumab and Vedolizumab Among Older Adults with Inflammatory Bowel DiseaseMoniyka Sachar, Pakdee Rojanasopondist, William Beaty, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 20, 2024
Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE RegistrySteven H Itzkowitz, Yue Jiang, Cristina Villagra, et al.
Inflammatory Bowel Diseases|July 29, 2022
Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal ResectionJordan E Axelrad, Terry Li, Salam P Bachour, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
The American Journal of Gastroenterology|November 17, 2023
Changes in Therapy Are Not Associated With Increased Remission in Patients With Crohn's Disease of the PouchMaia Kayal, Parakkal Deepak, Poonam Beniwal-Patel, et al.
Crohn'S & Colitis 360|July 31, 2023
Dietary Patterns Are Not Associated With Disease Activity Among Patients With Inflammatory Conditions of the Pouch in a Prospective CohortEdward L Barnes, Poonam Beniwal-Patel, Parakkal Deepak, et al.
Crohn'S & Colitis 360|September 9, 2022
Treatment Patterns and Standardized Outcome Assessments Among Patients With Inflammatory Conditions of the Pouch in a Prospective Multicenter RegistryEdward L Barnes, Parakkal Deepak, Poonam Beniwal-Patel, et al.
Inflammatory Bowel Diseases|July 22, 2024
Risankizumab Is Effective for The Management of Crohn's Disease of the PouchMaia Kayal, Elizabeth A Spencer, Matthew Smyth, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 15, 2019
Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel DiseasesJordan E Axelrad, Ahmad Bazarbashi, James Zhou, et al.
The American Journal of Gastroenterology|June 25, 2025
A Prospective Comparison of Ustekinumab and Antitumor Necrosis Factor α Therapy in the Treatment of Crohn's-Like Disease of the PouchEdward L Barnes, Laura Raffals, Taha Qazi, et al.
Therapeutic Advances in Gastroenterology|November 9, 2022
COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control studySimon J Hong, Sumona Bhattacharya, Aiya Aboubakr, et al.
Digestive Diseases and Sciences|September 16, 2025
Safety and Efficacy of Ustekinumab and Vedolizumab Among Older Adults with Inflammatory Bowel DiseaseMoniyka Sachar, Pakdee Rojanasopondist, William Beaty, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 20, 2024
Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE RegistrySteven H Itzkowitz, Yue Jiang, Cristina Villagra, et al.
Inflammatory Bowel Diseases|July 29, 2022
Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal ResectionJordan E Axelrad, Terry Li, Salam P Bachour, et al.
Pageof 9